{"prompt": "['MEIRAGTx', 'Gene Therapy for Achromatopsia (CNGA3)', 'An open label, multi-centre, Phase I/II dose escalation trial of a', 'recombinant adeno-associated virus vector (AAV8-hG1.7p.coCNGA3', 'for gene therapy of children with Achromatopsia owing to defects in', 'CNGA3', 'Version', 'Version 6.0', 'Date', '16Apr2021', 'Sponsor', 'MeiraGTx UK Il Ltd.', \"Sponsor's Protocol Number\", 'MGT012', 'Trial registration', 'EudraCT 2018-003431-29', 'Authorisation: Chief Investigator', 'Name', 'Role', 'Professor of Retinal Studies', 'UCL Institute of Ophthalmology', 'Signature', 'Date', 'Authorisation: Sponsor Representative', 'Name', 'Role', 'MeiraGTx Chief Medical Officer', 'Signature', 'Date', '16-Apr-2021 | 16:13 BST', 'CNGA3 MGT012 Protocol version 6.0 16Apr2021 Page 1 of 68']['MEIRAGTX', 'Table of Contents', '1', 'Administrative information', '7', '1.1', 'Compliance', '7', '1.2', 'Sponsor', '8', '1.3', 'Structured trial summary', '9', '1.4', 'Roles and responsibilities', '11', '2', 'Trial Diagram', '12', '3', 'Abbreviations', '13', '4', 'Introduction', '15', '4.1', 'Background and Rationale', '15', '4.1.1', 'Background', '15', '4.1.2', 'Pre-clinical data', '15', '4.1.3', 'Clinical data', '16', '4.1.4', 'Rationale', '17', '4.1.5', 'Assessment and management of risk', '17', '4.1.5.1', 'Risk of immune responses to AAV8-hG1.7p.coCNGA3', '18', '4.1.5.2', 'Risk of vector transmission to other organs', '18', '4.1.5.3', 'Risks of insertional mutagenesis and oncogenesis', '19', '4.1.5.4', 'Risk of germline transmission', '19', '4.1.5.5', 'Risk of surgical adverse effects', '19', '4.1.5.6', 'Risk of adverse effects of corticosteroids', '20', '4.1.5.7', 'Risks of investigations performed during assessment and follow up', '21', '4.1.5.8', 'Risk of rod photoreceptor dysfunction', '21', '4.1.5.9', 'Risk of thinning of the fovea', '21', '4.1.5.10', 'Risk of visual imbalance', '21', '4.1.5.11', 'Conclusion on the risk-benefit ratio', '22', '4.1.6', 'Explanation for Choice of Comparators', '22', '4.2', 'Objectives', '22', '4.2.1', 'Primary Objective', '22', '4.2.2', 'Secondary Objective', '22', '4.3', 'Trial Design', '22', '4.3.1.1 Separate longer term follow up study', '23', 'CNGA3 MGT012 Protocol version 5.0 09Jul2020 Page 2 of 68']['MEIRAGTx', '4.3.2', 'IMP administration Review and Dose Escalation Criteria and Process', '24', '4.3.2.1', 'Dose escalation criteria and Dose Limiting Events', '24', '4.3.2.2', 'Dosing process', '24', '4.3.2.2.1 Cohort 1', '24', '4.3.2.2.2 Cohort 2', '25', '4.3.2.2.3 Cohort 3', '25', '4.3.2.2.2.4 Adult Cohort-United States', '25', '4.3.2.2.5 Additional considerations', '25', '5', 'Methods', '26', '5.1', 'Site Selection', '26', '5.1.1', 'Study Setting', '26', '5.1.2', 'Site/Investigator Eligibility Criteria', '26', \"5.1.2.1 Principal Investigator's (PI) Qualifications and Agreements\", '27', '5.1.2.2', 'Resourcing at site', '27', '5.2', 'Site approval and activation', '27', '5.3', 'Participants', '28', '5.3.1', 'Eligibility Criteria', '28', '5.3.1.1', 'Participant selection', '28', '5.3.1.2', 'Participant Inclusion Criteria', '28', '5.3.1.3', 'Participant Exclusion Criteria', '29', '5.3.1.4', 'Eligibility Criteria for Individuals Performing the Interventions', '30', '5.3.1.5', 'Co-enrolment Guidance', '30', '5.3.1.6', 'Screening Procedures', '30', '5.3.1.6.1', 'Informed Consent Procedure', '30', '5.3.1.6.2', 'Screening Period', '31', '5.3.1.6.3 Enrolment', '32', '5.4', 'Intervention', '32', '5.4.1', 'Name and Description of Investigational Medicinal Product', '32', '5.4.1.1', 'ATIMPs Classified as Genetically Modified Organisms', '33', '5.4.1.2', 'Source of ATIMPs', '33', '5.4.1.3', 'Preparation and Labelling of the Investigational Medicinal Product', '33', '5.4.1.4', 'Description and Justification of Route of Administration and Dose', '33', '5.4.1.5', 'Name and Description of Each Non-Investigational Medicinal Drug (NIMP)', '34', 'CNGA3 MGT012 Protocol version 5.0 09Jul2020 Page 3 of 68']\n\n###\n\n", "completion": "END"}